首页> 外文期刊>Journal of Clinical Pathology >Recent insights into the molecular pathogenesis of mammary phyllodes tumours
【24h】

Recent insights into the molecular pathogenesis of mammary phyllodes tumours

机译:乳腺叶状肿瘤的分子发病机理的最新见解

获取原文
获取原文并翻译 | 示例
           

摘要

Phyllodes tumours (PTs) of the breast are true biphasic neoplasms within which interactions between the epithelium and stroma are critical for tumour development and progression. Despite numerous studies reporting the results of ancillary marker investigations in PTs, the current histological grading systems remain unreliable at predicting clinical outcome even when supplemented by these markers. As a consequence, there has been much interest in the prospect of using molecular/genetic techniques to develop a more robust "grading" system. This review focuses on recent cytogenetic and molecular studies investigating the pathogenesis of PTs and those correlating molecular findings with clinicopathological features of the tumours. Recent data highlight that intratumoural genetic heterogeneity is common in PTs and may account for the reported lack of correlation between histological grading and clinical behaviour. The entire spectrum of molecular aberrations in PTs are yet to be fully defined, however recent array-based studies using comparative genomic hybridisation have reported that copy number changes increase with the progression from benign PT to malignancy. Tumour recurrence and progression is likely to reflect the presence of under-recognised subclones. p~(16INK4a) (CDKN2A) inactivation also appears to be important in PT pathogenesis. Further additional studies will be required to identify and validate new prognostic markers and therapeutic targets in order to improve the diagnosis, classification, prediction of outcome and management of patients with this rare neoplasm. Data generated from modern sequencing technologies are likely to provide new insights into the disease and assist in this endeavour.
机译:乳房的叶状肿瘤(PTs)是真正的双相性肿瘤,其中上皮和基质之间的相互作用对肿瘤的发展和发展至关重要。尽管有大量研究报告了PT中辅助标记物研究的结果,但即使将这些标记物进行补充,当前的组织学分级系统仍无法可靠地预测临床结果。结果,人们对使用分子/遗传技术开发更稳定的“分级”系统的前景非常感兴趣。这篇综述着重于最近的细胞遗传学和分子学研究,研究了PT的发病机理以及那些将分子发现与肿瘤的临床病理特征相关的研究。最近的数据强调肿瘤内遗传异质性在PT中很常见,可能解释了组织学分级与临床行为之间缺乏相关性的报道。 PT中分子畸变的整个光谱尚未完全确定,但是最近使用比较基因组杂交的基于阵列的研究报告说,拷贝数变化随着从良性PT到恶性肿瘤的发展而增加。肿瘤的复发和进展可能反映了未充分认识的亚克隆的存在。 p〜(16INK4a)(CDKN2A)失活似乎在PT发病机理中也很重要。将需要进一步的研究来鉴定和验证新的预后标志物和治疗靶标,以改善这种罕见肿瘤患者的诊断,分类,结果预测和管理。现代测序技术产生的数据可能会提供对该疾病的新见解,并有助于这一努力。

著录项

  • 来源
    《Journal of Clinical Pathology》 |2013年第6期|496-505|共10页
  • 作者单位

    Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Building 94, Missenden Rd, Camperdown, Sydney, NSW 2046, Australia,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia;

    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia,Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia,Department of Molecular and Clinical Genetics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia,Faculty of Medicine, University of NSW, Australia;

    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia;

    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia;

    Department of Breast Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia;

    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia;

    Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia,Department of Molecular and Clinical Genetics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia;

    Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia,Department of Breast Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia;

    Department of Breast Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia;

    Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Hong Kong, Hong Kong;

    Department of Pathology, Singapore General Hospital, Singapore, Singapore;

    Department of Pathology, National Health System, Singapore, Singapore,Yong Loo Lin School of Medicine, University of Singapore, Singapore, Singapore;

    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia,Department of Pathology, School of Medicine, University of Western Sydney, Sydney, New South Wales, Australia,Cancer Pathology and Cell Biology Laboratory, Ingham Institute for Applied Medical Research,Department of Anatomical Pathology, Liverpool Hospital,Cancer Pathology, Bosch Institute, University of Sydney,South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号